Consensus about managing gastrointestinal and cardiovascular risks of nonsteroidal anti-inflammatory drugs?

Neville D. Yeomans

    Research output: Contribution to journalArticlepeer-review

    7 Citations (Scopus)

    Abstract

    In a recently published article in BMC Medicine, Scarpignato and colleagues present the results of a consensus conference that addressed several aspects of the management of pain in patients with osteoarthritis. The main areas covered include the relative safety in regard to gastrointestinal and cardiovascular adverse events of non-selective ‘traditional’ non-steroidal anti-inflammatory drugs (NSAIDs) versus cyclooxygenase-2 selective NSAIDs. The role of co-therapy with proton pump inhibitors in enhancing gastrointestinal safety is also reviewed. This commentary focuses on two areas that the consensus conference addressed, i) the whole length of gastrointestinal tract risk profile of the various NSAIDs (not just the ulcer risks in stomach and duodenum); ii) more recent information, but still some uncertainties, about the cardiovascular risks associated with the two classes of NSAID in general, and naproxen in particular.
    Original languageEnglish
    Number of pages3
    JournalBMC Medicine
    Volume13
    Issue number56
    DOIs
    Publication statusPublished - 2015

    Open Access - Access Right Statement

    © 2015 Yeomans; licensee BioMed Central. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.

    Keywords

    • anti-inflammatory drugs
    • gastrointestinal hemorrhage
    • management
    • peptic ulcer

    Fingerprint

    Dive into the research topics of 'Consensus about managing gastrointestinal and cardiovascular risks of nonsteroidal anti-inflammatory drugs?'. Together they form a unique fingerprint.

    Cite this